Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...
Browsing Tag: TYK2 therapy
Takeaways: Zasocitinib’s Phase 3 win over deucravacitinib suggests it could become a best-in-class oral TYK2 option for moderate-to-severe plaque psoriasis if regulators...